

# ISO/TS 5798:2022-04 (E)

## In vitro diagnostic test systems - Requirements and recommendations for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV -2) by nucleic acid amplification methods

---

<b>Contents</b>		<b>Page</b>
Foreword .....		v
Introduction .....		vi
<b>1</b>	<b>Scope .....</b>	<b>1</b>
<b>2</b>	<b>Normative references .....</b>	<b>1</b>
<b>3</b>	<b>Terms and definitions .....</b>	<b>1</b>
<b>4</b>	<b>Overview .....</b>	<b>7</b>
<b>4.1</b>	<b>SARS-CoV-2 .....</b>	<b>7</b>
<b>4.1.1</b>	<b>General .....</b>	<b>7</b>
<b>4.1.2</b>	<b>Pre-examination .....</b>	<b>9</b>
<b>4.1.3</b>	<b>Examination -- Overview .....</b>	<b>9</b>
<b>4.1.4</b>	<b>Post-examination .....</b>	<b>11</b>
<b>4.2</b>	<b>Nucleic acid amplification methods .....</b>	<b>11</b>
<b>4.2.1</b>	<b>Reverse transcription qPCR (RT-qPCR) .....</b>	<b>11</b>
<b>4.2.2</b>	<b>Reverse transcription digital PCR (RT-dPCR) .....</b>	<b>12</b>
<b>4.2.3</b>	<b>Isothermal amplification methods .....</b>	<b>12</b>
<b>5</b>	<b>Laboratory requirements .....</b>	<b>12</b>
<b>5.1</b>	<b>General .....</b>	<b>12</b>
<b>5.2</b>	<b>Biosafety requirements .....</b>	<b>13</b>
<b>5.2.1</b>	<b>Laboratory area .....</b>	<b>13</b>
<b>5.2.2</b>	<b>Risk control .....</b>	<b>13</b>
<b>5.2.3</b>	<b>Personal protective equipment (PPE) .....</b>	<b>13</b>
<b>5.3</b>	<b>General laboratory set-up .....</b>	<b>13</b>
<b>5.4</b>	<b>Instrumentation .....</b>	<b>14</b>
<b>5.5</b>	<b>Laboratory personnel .....</b>	<b>14</b>
<b>6</b>	<b>Design and development .....</b>	<b>14</b>
<b>6.1</b>	<b>Customer, patient and stakeholder needs .....</b>	<b>14</b>
<b>6.2</b>	<b>Intended use of analytical test .....</b>	<b>14</b>
<b>6.3</b>	<b>Institutional guideline strategy .....</b>	<b>15</b>
<b>6.3.1</b>	<b>Laboratory developed tests (LDTs) versus in vitro diagnostic medical devices (IVD medical devices) .....</b>	<b>15</b>
<b>6.3.2</b>	<b>Emergency use authorization .....</b>	<b>15</b>
<b>6.4</b>	<b>Clinical strategy .....</b>	<b>15</b>
<b>6.5</b>	<b>Design and development planning .....</b>	<b>16</b>
<b>6.5.1</b>	<b>Pre-examination of respiratory specimens for SARS-CoV-2 testing .....</b>	<b>16</b>
<b>6.5.2</b>	<b>Examination design specifications (analytical test specifications) .....</b>	<b>22</b>
<b>6.5.3</b>	<b>Design risk management .....</b>	<b>27</b>
<b>6.6</b>	<b>Optimization of reagents and methods .....</b>	<b>28</b>
<b>6.6.1</b>	<b>Selection of SARS-CoV-2 target sequences .....</b>	<b>28</b>
<b>6.6.2</b>	<b>Potential impact of variants of concern (VOCs) on the quality of NAAT diagnostic methods for detecting SARS-CoV-2 .....</b>	<b>28</b>
<b>6.6.3</b>	<b>Selection of amplification methods .....</b>	<b>28</b>
<b>6.6.4</b>	<b>Design and selection of primers .....</b>	<b>28</b>

6.6.5	Optimization of the reaction system .....	29
6.6.6	Determination of cut-off values .....	29
6.6.7	Verification and validation of test design .....	29
7	Verification for patient care .....	31
7.1	General .....	31
7.2	Confirmation of analytical performance characteristics .....	31
7.2.1	Accuracy .....	31
7.2.2	Limit of detection (LOD) .....	31
7.2.3	Inclusivity .....	32
7.2.4	Specificity .....	32
7.2.5	Robustness .....	32
7.3	Clinical evidence .....	33
8	Validation for patient care .....	33
8.1	General consideration .....	33
8.2	Clarification of the intended use .....	33
8.3	Performance with clinical specimens or samples .....	34
9	Design transfer to production .....	34
10	Implementation and use in the laboratory and reporting of results .....	34
10.1	Implementation and use in the laboratory .....	34
10.2	Reporting and interpretation of results .....	35
11	Quality assurance .....	36
11.1	Performance monitoring .....	36
11.2	Design change including optimization of analytical test .....	36
11.3	Interlaboratory comparison .....	37
	Annex A (informative) Nucleic acid amplification techniques .....	38
	Bibliography .....	41